Ori-Genic Biotech Corporation
Update：2025/01/01
Industries
Main Industry
Health Care
Main Product/Service
Pilatus Biosciences offers a unique opportunity to invest early at an attractive valuation. Our innovative therapies are already drawing strong interest from global pharmaceutical leaders, positioning us for high-value licensing deals or early M&A exits. In today’s selective market, Pilatus stands out through scientific innovation, capital efficiency, and a clear path to value creation.
Investment Highlights
01. About Us
Pilatus Biosciences is a preclinical-stage biotech company pioneering first-in-class biologics targeting metabolic checkpoints to reprogram the tumor microenvironment (TME)
02. Novel Science
Differentiated Immunometabolism approach targeting growing Cancer Immunotherapy and Metabolic Disease market
03. Lead Pipeline: PLT012
PLT012, a humanized anti-CD36 antibody, has demonstrated preclinical efficacy and received FDA Orphan Drug Designation for Liver cancers.
Investment Highlights
01. About Us
Pilatus Biosciences is a preclinical-stage biotech company pioneering first-in-class biologics targeting metabolic checkpoints to reprogram the tumor microenvironment (TME)
02. Novel Science
Differentiated Immunometabolism approach targeting growing Cancer Immunotherapy and Metabolic Disease market
03. Lead Pipeline: PLT012
PLT012, a humanized anti-CD36 antibody, has demonstrated preclinical efficacy and received FDA Orphan Drug Designation for Liver cancers.
Founded Year
2021
Unified Business No.
91118204
Status
Active
Number of Employees
0
Total Paid-in
Capital
30,000,000 (NT$)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
Location of Company
Taiwan
, Tainan City
Exclusive content for members
Members-only content. Please log in to access.
Introduction
Pilatus Biosciences, founded in 2022, pioneers first-in-class biologics targeting metabolic checkpoints to advance cancer immunotherapy. Drawing on groundbreaking research from the Ludwig Institute for Cancer Research (LICR) and the University of Lausanne (UNIL), the company drives transformative innovations in cancer treatment.
Supported by its U.S. holding entity, Pilatus Biosciences conducts cutting-edge research at the Biopole campus in Epalinges, Switzerland, and manages strategic partnerships and developments through its subsidiary at Taipei Bioinnovation Park in Taiwan.
Supported by its U.S. holding entity, Pilatus Biosciences conducts cutting-edge research at the Biopole campus in Epalinges, Switzerland, and manages strategic partnerships and developments through its subsidiary at Taipei Bioinnovation Park in Taiwan.
